H.262/MPEG-2 Part 2

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Drug development, Disease, NESS, Safety, NYSE, Policy, Senior, Food, Cystic fibrosis, Plasma protein binding, H.262/MPEG-2 Part 2, Workforce, Sputum, Clinical trial, Mortality, Insurance, Patient, Research, Part, FDA, Pharmacokinetics, Bacteria, Novartis, Conference, Pseudomonas aeruginosa, FEV1, Communication, CFU, Dermatology, Physician, Psoriatic arthritis, Fast Track, Part Two, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
  • In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
  • Net loss for the third quarter of 2023 was $7.9 million, compared to $6.8 million for the same period in 2022.
  • Net cash used in operating activities for the nine months ended September 30, 2023, was $15.0 million, compared to $21.9 million for the same period in 2022.

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Therapy, Table, OrbiMed, WEST, Bank statement, Phase II, Wart, CMC, GAAP, Part, H.262/MPEG-2 Part 2, Dermatology, Patient, Molluscum contagiosum, Part Two, Research, FDA, Carcinoma, Skin, Vaccine, Pharmaceutical industry, Cryptocurrency, Reinsurance, Bank

– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –

Key Points: 
  • – In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –
    WEST CHESTER, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2023.
  • Verrica recognized collaboration revenues of $0.2 million in the second quarter of 2023 and 2022 related to the Clinical Supply Agreement with Torii Pharmaceutical Col, Ltd (Torii).
  • Research and development expenses were $5.7 million in the second quarter of 2023, compared to $3.9 million for the same period in 2022.
  • General and administrative expenses were $5.9 million in the second quarter of 2023, compared to $5.2 million for the same period in 2022.

The Preparedness Playbook for Leadership in Difficult Times

Retrieved on: 
Tuesday, June 20, 2023
Cloud, Learning, Communication, TMG, Culture, CX, Research, Organization, 7 Mile (group), Friction, H.262/MPEG-2 Part 2, Caricature, Personality, System, Management, Extrusion

NEW YORK, June 20, 2023 /PRNewswire/ -- "Is there a playbook for the times we are in now? Is there a playbook for leaders who can define themselves with high integrity and high accountability, lead through the most difficult times, and not be high on the 'jerk' scale?"

Key Points: 
  • – Stephen Miles
    NEW YORK, June 20, 2023 /PRNewswire/ -- "Is there a playbook for the times we are in now?
  • Is there a playbook for leaders who can define themselves with high integrity and high accountability, lead through the most difficult times, and not be high on the 'jerk' scale?"
  • In this first of a 2-part series, " The Preparedness Playbook for Leadership in Difficult Times – Part 1 ," Miles and Tarkoff discuss the qualities needed by leaders from the CEO to the front line.
  • There's a lot of scorched earth and a lot of people who've lost trust and lost faith in the board or in the leadership."

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Therapy, Table, Bank statement, New Drug Application, CMC, NDA, GAAP, Part, H.262/MPEG-2 Part 2, Molluscum contagiosum, Dermatology, Treatment, PDUFA, Research, FDA, Carcinoma, Collaboration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Technology transfer, Food, Skin, Pharmaceutical industry, Bank

WEST CHESTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum
    WEST CHESTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2023.
  • “The first quarter of 2023 saw continued execution across our pipeline and strengthening of our financial position,” said Ted White, Verrica’s President and Chief Executive Officer.
  • On January 4, 2023, Verrica announced the successful completion of the technology transfer of bulk solution manufacturing of YCANTH to Piramal Pharma Solutions.
  • Costs of collaboration revenue were $68,000 for the first quarter of 2023, compared to $0.3 million for the same period in 2022.

BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Retrieved on: 
Wednesday, February 22, 2023
Pseudomonas aeruginosa, Data monitoring committee, Pediatrics, Physician, BOLT, Therapy, CFU, CF, Part Two, Cystic fibrosis, Safety, NYSE, Patient, Infection, Disease, FEV1, Clutch (eggs), Food, Mortality, CFTR, International, Part, NESS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Cystic Fibrosis Foundation, H.262/MPEG-2 Part 2, Pharmaceutical industry, Medical imaging

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced positive results from Part 1 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”).

Key Points: 
  • “We are very excited to share these positive results from Part 1 of our Phase 1b/2a CF study,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • The BiomX Phase 1b/2a clinical trial is the first reported double blind placebo-controlled study evaluating a cocktail-based phage product to demonstrate notable reductions in bacterial burden in cystic fibrosis.
  • In September 2021, BX004 was cleared by the U.S. Food and Drug Administration to initiate a Phase 1b/2a study in CF patients with chronic pulmonary infections caused by P. aeruginosa.
  • BiomX management will host a conference call and webcast today at 9:00 am to review the results of the Phase 1b/2a trial results.